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Abstract
Stimulation of resident cells by NF-kB activating cytokines is a central element of inflammatory and degenerative disorders
of the central nervous system (CNS). This disease-mediated NF-kB activation could be used to drive transgene expression
selectively in affected cells, using adeno-associated virus (AAV)-mediated gene transfer. We have constructed a series of AAV
vectors expressing GFP under the control of different promoters including NF-kB -responsive elements. As an initial screen,
the vectors were tested in vitro in HEK-293T cells treated with TNF-a. The best profile of GFP induction was obtained with a
promoter containing two blocks of four NF-kB -responsive sequences from the human JCV neurotropic polyoma virus
promoter, fused to a new tight minimal CMV promoter, optimally distant from each other. A therapeutical gene, glial cell
line-derived neurotrophic factor (GDNF) cDNA under the control of serotype 1-encapsidated NF-kB -responsive AAV vector
(AAV-NF) was protective in senescent cultures of mouse cortical neurons. AAV-NF was then evaluated in vivo in the kainic
acid (KA)-induced status epilepticus rat model for temporal lobe epilepsy, a major neurological disorder with a central
pathophysiological role for NF-kB activation. We demonstrate that AAV-NF, injected in the hippocampus, responded to
disease induction by mediating GFP expression, preferentially in CA1 and CA3 neurons and astrocytes, specifically in regions
where inflammatory markers were also induced. Altogether, these data demonstrate the feasibility to use disease-activated
transcription factor-responsive elements in order to drive transgene expression specifically in affected cells in inflammatory
CNS disorders using AAV-mediated gene transfer.
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Introduction
The clinical implementation of drug-dependent regulatable
viral vectors for gene therapy has been hampered by the adverse
effects of the pharmacologic inducer and the immunogenicity of
the artificial transactivator generally containing viral and/or
bacterial elements [1,2]. Ideally, gene therapy for CNS diseases
should be modulated according to the severity and the evolution of
the disease. In addition, the transgene should be specifically
expressed in the affected brain region and cell types. As an
alternative to drug-mediated regulatory systems, we considered the
possibility that regulatory DNA sequences binding transcription
factors that are activated in pathological conditions could be used
to generate pathology-inducible promoters responding to specific
endogenous stimuli [3–5].
The NF-kB family of transcription factors consists of 5
members, defined by their Rel homology region, forming homo-
and heterodimer complexes [6].
While inactive, NK-kB dimers are bound to IkB proteins and
retained in the cytoplasm. During activation, IkB is degraded and
the NF-kB transcription factors are released and translocate to the
nucleus where they regulate the transcription of numerous genes
[7]. Stimulation of the NF-kB pathway is a key pathologic
component of numerous CNS disorders [8]. In particular, NFkB
activation is a major pathogenic component in the kainic acid
(KA)-induced rat model of status epilepticus (SE) [9,10], one of the
most widely used and best characterized animal models for
temporal lobe epilepsy (TLE) [11–14]. This model displays
characteristic neuropathological aspects of the disease including
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hippocampal sclerosis (neuron loss and gliosis), neuroinflamma-
tion, synaptic reorganization, such as mossy fibre sprouting, and
the chronic recurrence of spontaneous seizures [15–19].
NFkB activation resulting from increases in inflammatory
cytokines has also been involved in pathological processes related
to aging [20] and Alzheimer Disease [21]. Additional data suggest
that NFkB activation is not an autocompensatory response, since
NFkB activation fails to protect neurons against apoptosis
associated with long-term culturing or dual TNFa and amyloid-
beta toxicity [22].
Harnessing disease-mediated NF-kB activation to drive trans-
gene expression in CNS cells could constitute an interesting
intracellular approach to anti-inflammatory intervention [23].
Several lines of transgenic reporter mice using tandem NFkB-
responsive promoter sequences have exhibited heterogeneous
phenotypes. This can likely be explained by the fact that the Rel
family of transcription factors includes numerous variants whose
abundance varies depending on the tissue and which bind with
differential affinities to different variants of the NFkB response
element (NFkB-RE). We therefore reviewed these data carefully
prior to selecting NFkB-REs for testing in our regulatable gene
therapy vectors. Transgenic mice using the NFkB responsive
sequence from the Igk light chain promoter mainly express the
reporter gene in immune organs and intestine and transgene
expression is further inducible by TNFa, IL1b or LPS in other
organs such as lungs and liver [24]. In contrast, the NFkB
responsive element present in the HIV promoter is expressed in
immune organs, but is also constitutively active in the CNS [25].
The regulatory region of human neurotropic polyoma virus JCV
which contains a NFkB-RE variant that differs from the HIV
sequence by only one nucleotide [26] is active in infected
astrocytes and oligodendrocytes presumably due to TNFa
stimulation of these glial cells [27].
A neuroinflammation-responsive AAV vector based on JCV
NFkB-RE consensus transcriptional sequences was designed. We
first tested this NFkB-inducible vector in an in vitro model of brain
aging [28] and showed that its delivery of glial cell line-derived
neurotrophic factor (GDNF) cDNA under the control of the
NFkB-inducible promoter enhanced survival of aging cortical
neurons in culture. We subsequently showed that hippocampally-
delivered, the NFkB-inducible AAV vector responded to systemic
KA injection in neurons and astrocytes in specific subregions of
the CA1, CA3 hippocampal layers and stratum orens where
inflammatory markers were also induced. Altogether, these results
bode positively for the utilization of our novel pathology-inducible
vector design for anti-inflammatory gene transfer applications.
Materials and Methods
Plasmids
The pNFkB-d2EGFP plasmid containing 4 NFkB responsive
element (NFkBRE) fused to a minimal thymidine kinase promoter
(mTK) was purchased from Clontech (Palo Alto, CA, USA) The
pHpaI-EGFP self-complementary AAV vector was a kind gift
from D.McCarty and RJ Samulski [29].
We first constructed pSC-NF4-mTK-d2EGFP by replacing the
EcoRI-SalI fragment of pHpaI-EGFP containing the CMV
promoter, EGFP coding sequence and SV40 polyA with a NotI-
SalI fragment from pNFkB-d2EGFP containing a transcription
blocker site, a composite NFkB-responsive promoter (4 copies of
the NFkB-responsive element fused to a minimal thymidine kinase
promoter), destabilized GFP (d2EGFP) and SV40 polyA. Into the
obtained vector, d2EGFP was replaced with EGFP to generate
pSC-NF4-mTK-EGFP (Fig. 1A). The pSC-mCMVD2-EGFP was
derived by replacing the mTK promoter in pSC-NF4-mTK-
EGFP with a new modified minimal CMV promoter (mCMV)
named mCMVD2 in which sequences 59and 39to the TATA box
were deleted. To obtain pSC-NF4-d1-EGFP and pSC-NF4-d3-
EGFP we increased the distance between the NFkBRE and the
mCMVD2 promoter by introducing stuffer sequences of various
lengths. The pSC-NF-Ctrl was obtained by excising a fragment
containing NFkBRE in pSC-NF4-mCMVD2-EGFP. To construct
pSC-NF8-d1-EGFP and pSC-NF12-EGFP, we replaced the NF4
in pSC-NF4-mCMVD2-EGFP respectively by two or three blocks
of 4 NFkBRE, separated by 16 bp. The pSC-NF8-d1-GDNF
vector was obtained by replacing the EGFP coding sequence in
pSC-NF8-d1-EGFP by the human GDNF cDNA (a kind gift from
Dr Nicole Deglon, Lausanne Switzerland).
Cell Line
The HEK-293T cell line was purchased from Q-One Biotech
(Glasgow, UK) and cultured in Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 10% FCS (Gibco BRL, Life
Technologies, Merelbeke, Belgium).
Transfections
For the analysis of the inducibility of the vectors, HEK-293T
cells were transfected using the calcium phosphate coprecipitation
method. Fifty-thousand cells in 6-wells were transfected with
250 ng DNA. Forty-eight hours later and 5 hours before analysis,
transfected cells were treated or not treated with TNFa
(Invitrogen) (100 ng/ml). Cells transfected with AAV-NF-EGFP
were analyzed for GFP expression on a FACStar analyser/sorter
(Becton Dickinson). To analyse the inducibility of AAV-NF-
hGDNF vectors in HEK 293T, the supernatants were harvested
4 h after changing the medium to measure GDNF concentration
using a commercial ELISA assay (Human GDNF CytoSets,
catalog #CHC2423, BioSource, Nivelles, Belgium). The transfec-
tion efficiency was normalized using a plasmid constitutively
expressing GFP protein.
Viral Production
To produce recombinant AAV2/1 viral stocks, HEK-293T cells
(5.06106 cells seeded on 10 cm plates) were cotransfected, in a 1:1
molar ratio, with the vector plasmid (3 mg/plate) together with the
helper/packaging plasmid pD1rs (10 mg/plate) expressing the
AAV viral genes (rep gene from AAV serotype 2 and cap gene
from AAV serotype 1) and the adenoviral genes required for AAV
replication and encapsidation (Plasmid Factory, Heidelberg). Fifty
hours post-transfection, the medium was discarded and the cells
were harvested by low-speed centrifugation and resuspended in
Tris pH 8.0, NaCl 0.1 M. After three cycles of freezing/thawing,
the lysate was clarified by 30 min centrifugation at 10 000 g,
treated with DNase at 37uC for 30 min, and centrifuged at 10
000 g for 30 min to eliminate the residual debris. The virus was
further purified by iodixanol gradient followed by QXL-sepharose
chromatography, according to a well-established method [30].
Viral genomes (vg) were titrated by quantitative PCR as previously
described [31]. Titers were 1.9561010 and 7.361011 vg/ml
respectively for rAAV1-NF8-d1-EGFP and rAAV1-NF8-d1-
hGDNF.
Cultures and Infection of Cortical Neurons
Neuronal cultures were prepared from embryonic day 16
Sprague-Dawley rat fetuses using methods similar to those
described previously [32].
Nuclear Factor-kB-Inducible Viral Vector
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Neurons were plated in 96-well or 48-well dishes (CostarTM)
previously coated with poly-L-lysine (MW 30,000–70,000).
Half of the medium was replaced, weekly, with freshly prepared
NeurobasalTM medium (Invitrogen) supplemented with 2% B27
(Invitrogen), 16 penicillin-streptomycin, 0,5 mM L-glutamine,
and 15 mM KCl. On in vitro Day 3, cells were infected at a
multiplicity of infection of 104 vg/cell.
Immunocytochemistry
Primary cultures were fixed with 4% paraformaldehyde (PFA)
for 20 min at 4uC. Cultures were washed 3610 min with PBS and
then incubated for 1 h in a blocking solution of PBS supplemented
with 10% Bovine Serum Albumin (PAA laboratories GmbH,
Austria) and 0.1% Triton in PBS. The cells were then incubated
overnight at 4uC in a blocking solution containing mouse
monoclonal anti-NeuN antibody (1:400, Chemicon), goat poly-
clonal anti-PSD95 (1:500, Abcam).
Cells were washed 3610 min with PBS and then incubated for
1 h with a fluorescent secondary Cy3-conjugated goat anti-mouse
antibody (1:1000, Jackson ImmunoResearch Laboratories), Alexa
660 donkey anti-goat antibody (1:500, Invitrogen) followed by
3610 min PBS washes.
Images of immunostained cells were acquired with a BD
pathway 435 Openaccess instrument for cell counting. Image
analysis was performed with ImageJ software (US NIH).
For activated NFkB staining, the same protocol was applied
using a mouse monoclonal IgG3 anti-activated NFkB recognizing
an epitope overlapping the nuclear location signal of the p65
subunit of the NFkB heterodimer thus selectively binding to the
activated form of NFkB [33] (Millipore, catalog # MAB3026).
The antibody was diluted 1:100 as primary antibody and a biotin-
conjugated donkey anti-mouse IgG (Jackson ImmunoResearch,
cat number: 715-065-150) diluted 1:500 was used as secondary
antibody. For nuclear counterstainings, cells were incubated in the
Figure 1. Description of the NF-kB-responsive AAV vectors. A. Schematic diagram of NF-kB-responsive AAV vectors used in this study. ITR:
AAV Inverted Terminal Repeat; TB: Transcriptional Blocker; NFkBRE (4X): four copies of the JC virus NFkB consensus sequence; mTK: herpes simplex
virus minimal thymidine kinase promoter; SD/SA: Splice Donor/Splice Acceptor sequence [72]; mCMVD2: improved minimal CMV promoter; d1, d3:
distance separating the last NFkB consensus sequence and the minimal promoter, respectively, 31 and 71 bp. B. Sequence analysis of the
transcription factor binding sites within the minimal CMV and the minimal CMV D2 promoters. The mCMV promoter originates from position 252 to
position +77 in the wild-type promoter [45]. Analysis of the mCMV sequences highlighted the presence of several transcription factor binding sites :
AP2, LFA-1, CRE-1, IFNc, XRE-1 and GCF. The mCMVD2 was obtained by deleting the sequence upstream of the TATA box (252 to 232) and the
sequence downstream of the IFNc site (+17 to +77) resulting in the removal of AP2, XRE-1 and GCF sites.
doi:10.1371/journal.pone.0053156.g001
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Hoescht 33258 dye (Sigma-Aldrich) diluted at 1 mg/ml in TBS for
15 min. Three 10 min washes in TBS of were performed between
each step. Images of immunostained cells were obtained by
confocal microscopy (Lasersharp version 3.2 (Biorad, Hercules,
CA) coupled to Axiovert 100 microscope, (Carl Zeiss, Gottingen,
Germany)). The intensity of the staining of individual nuclei was
quantified by measuring optical densities using the Image J
software (NIH, USA).
Glial Cell Line-derived Neurotrophic Factor (GDNF)
Determination by ELISA
Medium was harvested from rAAV1-NF8-d1-EGFP- and
rAAV1-NF8-d1-hGDNF-infected cortical neuron cultures at the
indicated time points.GDNF concentrations were measured using
a commercial ELISA assay (Human GDNF CytoSets, catalog
#CHC2423, BioSource, Nivelles, Belgium) and expressed in pg/
ml. Recombinant human GDNF (provided by the manufacturer)
was used to establish the standard curve.
Kainic Acid-induced Post-status Epilepticus Ral Model of
Temporal Lobe Epilepsy
Intracerebral AAV vector injections. Adult male Wistar
rats (Charles River) weighing approx. 200 g were housed and
treated according to the Belgian law. The protocols were in
accordance with national rules on animal experiments and were
approved by the Ethics Committee of the Faculty of Medicine of
the ‘‘Universite´ Libre de Bruxelles’’. Animals were anesthetized
with a mixture of ketamine (Imalge`ne 1000, Merial; 100 mg/kg)
and xylazin (Rompun, Bayer; 10 mg/kg) and placed in a Kopf
stereotaxic frame (Kopf Instruments, Tujunga, CA, USA). The
injection coordinates in the hippocampus were 4.8 mm posterior,
4.6 mm lateral to bregma, and 4.4 mm below the dural surface
and in the cerebellum: 11.96 mm posterior, 2.0 mm lateral to
bregma, and 2.5 mm below the dural surface. The injection rate
was 0.2 ml/min. The needle was left in place for 1 min before a
slow withdrawal over an additional minute.
Intraperitoneal kainic acid injections. The induction of
status epilepticus was performed as described earlier [34,35].
Briefly, consecutive intraperitoneal kainic acid (KA) injections
(5 mg/kg, diluted in PBS, NanocsH) were administered with a one
hour interval. If a rat was nearing SE, half-doses (2.5 mg/kg) were
given in order to reduce mortality. Control rats were injected with
saline (NaCl 0.9%). Based on previous studies in which these
animals were chronically monitored with video-electrocorticogra-
phical recordings, nearly all rats develop spontaneous seizures
(99.95%) with the first unprovoked seizure recorded 11.6866.86
days post-status epilepticus (n = 35).
This is in line with other groups applying the same status
epilepticus induction procedure with individually-dosed kainic
acid [16,36].
Briefly, consecutive intraperitoneal kainic acid (KA) injections
(5 mg/kg, diluted in PBS, NanocsH) were administered with a one
hour interval. If a rat was nearing SE, half-doses (2.5 mg/kg) were
given in order to reduce mortality. Control rats were injected with
saline (NaCl 0.9%).
Animals were sacrificed one week after intraperitoneal KA
injection and perfused intracardiacally first with saline, then with
4% paraformaldehyde (PF4). Brains were postfixed for 24 hours in
PF4.
The experiment was repeated 3 times with similar results.
Immunofluorescence on Brain Sections
GFP labeling. Coronal brain sections (50 mm) obtained using
a vibratome (Leica Microsystems, Wetzlar, Germany) were
sequentially incubated in: i) THST (50 mM Tris, 0.5 M NaCl,
0.5% Triton X100 (Merck, Frankfurter, Germany) pH7.6)
containing 10% horse serum for 2 hours; ii) polyclonal rabbit
anti-GFP (1:3000, Molecular Probes, Invitrogen, Carlsbad, CA)
diluted in THST containing 5% horse serum for 16 hours at 4uC;
iii) donkey anti rabbit IgG conjugated with biotin (Amersham, GE
Healthcare, Munich, Germany) diluted 1:600 in THST containing
5% horse serum, 2 hours at room temperature; iv) streptavidin
conjugated to cyanine 2 (1:300; Jackson ImmunoResearch, West
Grove, PA) in THST containing 5% horse serum, 2 hours at room
temperature. Three washings in TBS (Tris 10 mM, NaCl 0.9%,
pH7.6) of 10 min. were performed between each step.
Sections were mounted using FluorSave mounting fluid for
fluorescence (Calbiochem, Merck, Frankfurter, Germany) and
photographed using a Zeiss Axiophot 2 microscope equipped with
FITC and TRITC filters (Car Zeiss, Go¨ttingen, Germany) as well
as an AxioCam digital camera (Carl Zeiss, Gottingen, Germany).
Images were acquired as jpeg files using the KS300 software (Car
Zeiss, Gottingen, Germany).
The number of GFP-positive cells was evaluated by stereological
procedures based on the Cavalieri principle (Sterio, 1984). For
each animal, serial sections with an interval of 500 mm were
analyzed by means of the optical fractionator of the Stereo-
investigator software (MBF Bioscience, Williston, VT) connected
to the microscope with a CCD video camera (Leica Microsystems,
Wetzlar, Germany).
GFP:NeuN and GFP:GFAP co-labelings. For double im-
munofluorescence, these incubations were combined with mouse
monoclonal antibodies (anti-NeuN (1:200, Chemicon, Millipore,
Billerica, MA) or anti-glial fibrillary acid protein (GFAP, 1:200,
Chemicon, Millipore, Billerica, MA)) (step ii); and donkey anti-
mouse IgG coupled to cyanine 3 (1:200; Jackson ImmunoRe-
search, West Grove PA) in THST containing 5% horse serum)
(step iv).
Sections were mounted using FluorSave mounting fluid for
fluorescence (Calbiochem, Merck, Frankfurter, Germany).
Co-labeling analysis were performed by confocal microscopy on
pictures taken on at least three different sections within the
transduction zone using an automatic image analysis system
(Lasersharp version 3.2 (Biorad, Hercules, CA) coupled to
Axiovert 100 microscope, (Carl Zeiss, Gottingen, Germany)).
Figure 2. In vitro TNFa-mediated induction of NF-kB-responsive AAV vectors. HEK-293T cells were transfected with AAV-NF-EGFP (A) or
with AAV-NF-hGDNF (B) vectors using the calcium phosphate coprecipitation method. 56105 cells in 6-wells were transfected with 250 ng DNA.
Forty-eight hrs later, transfected cells were treated or not with TNFa (100 ng/ml) for 5 hrs. HEK-293T transfected with AAV-NF-EGFP were analyzed for
GFP expression on a FACStar analyser/sorter (Becton Dickinson) (A). To analyse the inducibility of AAV-NF-hGDNF vectors in HEK-293T, the
supernatant were harvested 4 h after changing the medium to measure secreted GDNF concentrations by a commercial ELISA assay (Human GDNF
CytoSets, catalog #CHC2423, BioSource, Nivelles,Belgium) (B). For both AAV-NF8-d1-hGDNF and AAV-NF12-d1-hGDNF vectors, the differences
between the TNFa-treated and untreated cultures were highly significant. The differences between the basal levels and the induced levels for AAV-
NF8-d1-hGDNF versus AAV-NF12-d1-hGDNF are not significant (B). (***, p,0.001; ns, p.0,05, one-way ANOVA Newman-Keuls Multiple Comparison
Test). Data are from one representative out of three experiments (3 separate transfections). Bars represent means 6 standard deviations (SD) (A) or
means 6 standard error of the means (SEM) (B) from triplicate wells. A.U., arbitrary units.
doi:10.1371/journal.pone.0053156.g002
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Pictures were then processed and analysed with the Image J
software (NIH, USA).
GFP:IbaI co-labeling. For GFP:IbaI double immunofluo-
rescence, the above described GFP labeling was combined with
goat anti-IbaI (Abcam, cat number: ab 5076) followed by a donkey
anti-goat A.568 antibody (Molecular probes, cat number A-11057)
diluted 1:500.
GFP:Olig2 co-labeling. For GFP:Olig2 double immunoflu-
orescence, a chicken monoclonal anti-GFP antibody (Abcam,
Cambridge, UK) at a 1:1000 dilution was combined with rabbit
polyclonal anti-Olig2 IgG (diluted 1:500; Chemicon/EMD
Millipore).
In order to better visualize the structure of the tissue, cerebellar
sections were incubated in the Hoescht 33258 dye (Sigma-Aldrich)
diluted at 1 mg/ml in TBS for 30 min. Three washings in TBS of
10 min were performed between each step.
Sections were mounted using Glycergel Mounting Medium for
fluorescence (Dako, Belgium, cat number: C0563).
Confocal Microscopy
Co-labeling analysis was performed on pictures taken on at least
three different sections using a LSM510 NLO multiphoton
confocal microscope fitted on an Axiovert M200 inverted
microscope equipped with C-Apochromat 406/1.2 N.A. and
636/1.2 N.A. water immersion objectives (Zeiss, Iena, Germany).
The 488 nm excitation wavelength of the Argon/2 laser, a main
dichroic HFT 488 and a band-pass emission filter (BP500–
550 nm) were used for selective detection of the green fluoro-
chrome (Cy2, Alexa 488).
The 543 nm excitation wavelength of the HeNe1 laser, a main
dichroic HFT 488/543/633 and a long-pass emission filter
(BP565–615 nm) were used for selective detection of the red
fluorochrome (Cy3).
The nuclear stain Hoechst was excited in multiphotonic mode
at 760 nm with a Mai Tai tunable broad-band laser (Spectra-
Physics, Darmstad, Germany) and detected using a main dichroic
HFT KP650 and a band-pass emission filter (BP435–485 nm).
Optical sections, 2 microns thick, 512 by 512 pixels, were
collected sequentially for each fluorochrome. Z-stacks with a focus
step of 1 micron were collected.
The data-sets generated were merged and displayed with the
Zeiss Zen 2009 software and exported in LSM image format.
Countings were performed with the ImageJ 1.46 a software
(NIH, USA). Figures were prepared with Adobe Photoshop CS3
software.
Chromogenic Immunohistochemistry on Brain Sections
For CD11b staining, vibratome coronal brain sections (50 mm)
were sequentially incubated in: i) 3% H2O2 in TBS (Tris 10 mM,
0.9% NaCl, Ph 7.6) for 30 min.; ii) THST (50 mM Tris,
0.5 M NaCl, 0.5% Triton X100 pH 7.6) containing 10% horse
serum for 1 hour; iii) mouse monoclonal anti-CD11b (1:500,
Serotec, MorphoSys, Dusseldorf, Germany) in THST containing
5% horse serum overnight a` 4uC; (step iii), then goat anti-mouse
IgG conjugated with HRP (Molecular Probes, Invitrogen,
Carlsbad, CA, from TSA kit) diluted in Blocking Reagent
provided with the TSA kit (Molecular Probes, Invitrogen,
Carlsbad, CA) was added for 2 hours at room temperature (step
iv); and v) diaminobenzidine (Vector, NTL Laboratories, Brussels,
Belgium), according to the manufacturer’s protocol. Sections were
photographed using a Zeiss Axiophot 2 (Carl Zeiss, Gottingen,
Germany) microscope.
For activated NFkB staining, the same protocol was applied
using a mouse monoclonal IgG3 anti-activated NFkB recognizing
an epitope overlapping the nuclear location signal of the p65
subunit of the NFkB heterodimer thus selectively binding to the
activated form of NFkB [33] (Millipore, catalog # MAB3026).
The antibody was diluted 1:100 as primary antibody (step iv) and a
goat anti-mouse IgG conjugated with biotin diluted 1:200 was
used as secondary antibody (step v). Densitometric analysis of the
stainings was performed using the image J software (NIH, US).
Statistical Analysis
All the statistical analysis was performed using the GraphPad
Software.
Results were expressed as mean 6SEM and statistical
significance was evaluated with one-way ANOVA Newman-Keuls
or student T-test. Differences were considered as significant when
p,0.05. Correlation analysis was evaluated with Pearson’s
correlation test.
Results
1. Design and in vitro Evaluation of NFkB-inducible AAV
Vectors
NFkB-inducible reporter cassettes were constructed by fusing a
minimal promoter with several repeats of the NFkB responsive
elements (NFkB–RE) from the non-coding regulatory region of JC
virus [26] upstream to an EGFP reporter gene. The promoter-
reporter cassettes were then introduced in a self-complementary
AAV vector which allows a rapid onset of transgene expression
[37,38]. In order to avoid influence of the AAV ITR promoter/
enhancer activity on the NFkB-RE-containing promoter [39,40],
a transcriptional blocker site [41] was placed between the left ITR
and the test promoters and a bidirectional SV40 polyA was placed
between the transgene cDNA and the right ITR [42] (see Fig. 1).
Two different minimal promoters fused to four repeats of the
NFkB-RE were compared. These consisted of a minimal
thymidine kinase promoter [43] and a minimal CMV promoter
[42] from which other putative transcription factor binding sites
Figure 3. Enhanced neuronal survival in senescent cultures of cortical neurons mediated by rAAV2/1-NF8d1-driven GDNF
transgene expression. (A) Embryonic day 16 cortical neurons were maintained in 96 wells plates for 60 days. Cultures were fixed and stained with
NeuN (a neuronal specific nuclear protein) or PSD95 (a neuronal postsynaptic density protein) a class of anchoring proteins which serve to localize
various neuronal ion channels to post-synaptic densities antibodies. The number of NeuN-positive or PSD95-positive neurons is significantly higher in
cultures treated with rAAV2/1-NF8d1-GDNF as compared to rAAV2/1-NF8d1-EGFP (CtrL) (p,0.05; student test, n = 10). Bars represent means 6 SEM.
(B) Similar cultures seeded on coated glass coverslips were fixed at day 10, day 21 and day 47 and stained with antibodies directed against activated
NFkB followed by a secondary antibody coupled with cyanine 2. Shown are confocal microscopy photographs. Bars represent 50 mM. The mean
optical density of the nuclei was measured using the Image J software. Differences between day 10 (n = 39) and day 21 (n = 59) or day 47 (n = 57)
were respectively highly significant (**; p,0.001) and very highly significant (###; p,0.0001). The experiment was repeated twice with similar
results. (C) Culture media from rAAV1-NF8-d1-GDNF- and rAAV1-NF8-d1-EGFP-infected cultures were harvested from day 5 to day 42 post-infection
and GDNF concentrations (pg/ml) were measured using ELISA assay. For rAAV1-NF8-d1-GDNF-infected cultures, all values, except at day 5, were
significantly higher (***; p,0.0001; n = 10 for rAAV1-NF8-d1-hGDNF and n= 8 for rAAV1-NF8-d1-EGFP) than the basal level (medium from rAAV1-NF8-
d1-EGFP-infected cultures). The experiment was repeated twice with similar results.
doi:10.1371/journal.pone.0053156.g003
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upstream and downstream of the TATA box were deleted,
retaining only 3 downstream consensus sequences (CRE-1, LFA-1
and IFNc). This minimal promoter will be hereafter designated as
mCMVD2 (see Fig. 1A and Fig. 1B). The pSC-NF-Ctrl-EGFP
plasmid containing mCMVD2, TB and the SV40 polyA but
devoid of NFkB-responsive sequences was used as a control.
The test vectors were transfected into HEK-293T cells, which
were left untreated or exposed to TNFa (100 ng/ml). HEK-293T
cells were chosen for these studies based on previous data
suggesting that they have little or no NFkB activation under basal
conditions [44]. Fig. 2A shows that the use of the mCMVD2
promoter resulted in a higher cytokine-induced level of GFP
expression than the minimal TK promoter (p,0.001, one way
ANOVA, Newman-Keuls multiple comparison Test) without
increasing basal level and thus it was selected for the following
constructions. As expected, the control (pSC-NF-CtrL-EGFP and
pSC-NF-CtrL-hGDNF) vectors were not inducible by TNFa
(p.0.05) (Fig. 2A and 2B).
i) Optimisation of the distance between NFkB-RE and
mCMVD2. The distance between enhancers and the transcrip-
tion initiation site is known to be important for the interaction
between the proteins involved in the trancriptional complex [45].
In order to optimize the inducibility of the AAV-NF vector, we
tested various spacings between the NF-kB repeats and the TATA
box of the mCMVD2 promoter.
Increasing the distance from 6 bp (pSC-NF4-mCMVD2) to
31 bp (pSC-NF4-d1) or 71 bp (pSC-NF4-d3) resulted in significant
(p,0.01) distance-dependent decreases of the basal reporter level.
The profile was different for the induced levels however.
Inducibility was maintained up to a distance of 31 bp (p.0.05,
pSC-NF4-mCMVD2 versus pSC-NF4-d1) and decreased at a
distance of 71 bp (p,0.001, pSC-NF4-mCMVD2 versus pSC-
NF4-d3). On the basis that a spacing distance of 31 bps
maintained high inducible expression levels while decreasing basal
expression (compared to the shorter spacing of 6 bp) the 31 bp
spacing incorporated in pSC-NF4-d1 was carried forward for
further development.
ii) Optimisation of the number of NFkB-RE. Starting
from pSC-NF4-d1 (with 4 NFkB-REs), the number of repeats was
increased to 8 and 12 (corresponding to pSC-NF8-d1 and pSC-
NF12-d1; see Fig. 1A). pSC-NF8- d1 and pSC-NF12-d1 showed
basal levels of GFP expression similar to pSC-NF4-d1 whereas the
TNFa-induced levels were higher than pSC-NF4-d1 for both
plasmids (p,0.01, pSC-NF4-d1 versus pSC-NF8-d1 and pSC-
NF4-d1 versus pSC-NF12-d1) (Fig. 2A). Using two reporter genes
(EGFP and hGDNF), no significant difference in TNFa-induced
levels was observed between pSC-NF8-d1 and pSC-NF12-d1
(Fig. 2A and 2B). Based on its retaining a larger residual cloning
capacity (approx. 900 bp), pSC-NF8-d1 vector was selected for
further testing.
2. Enhanced Survival of Senescent Cortical Neurons
Mediated by NF-kB-inducible GDNF Expression
We then wanted to test whether an effect of a therapeutic
transgene could be conveyed by the rAAV2-NF8-d1 recombinant
virus. To address this question, the rAAV2-NF8-d1 vector
expressing the human GDNF cDNA was evaluated in an in vitro
model of brain aging.
To determine which capsid serotype would be suitable for our
primary cells in culture, we evaluated control cultures infected
with AAV vectors expressing EGFP under the control of the CMV
promoter transencapisdated into serotype 1, 2 and 5 capsids (5,000
cells/well; 104 vg/cell). This relatively low multiplicity of infection
was chosen to avoid previously described AAV vectors-related
toxicity in primary neurons cultures [46]. GFP-positive cells were
observed from day 3 after infection and their detectable numbers
reached 170 (rAAV2/1), 40 (rAAV2/2) and 92 (rAAV2/5) at 5
days post-infection (data not shown). Therefore, serotype 1 was
selected for further experiments.
We then proceeded to test the efficacy of our new vector in
long-term cultures of E16 cortical neurons and astrocytes in
serum-free medium. In this model, neurons gradually mature and
form synapses but eventually undergo apoptosis starting at
approximately 35–40 days in vitro. 5,000 cells were infected with
rAAV2/1-NF8-d1-EGFP (n= 10) as a control or rAAV2/1-NF8-
d1-GNDF (n= 10) at a multiplicity of 104 vg/cell.
After 60 days, cells infected with the rAAV2/1-NF8-d1 vectors
were fixed and expression of NeuN (a neuronal specific nuclear
protein also known as Fox3a) and PSD95 (a neuronal postsynaptic
density protein) were evaluated. The number of NeuN-positive
and PSD95-positive structures was significantly higher in the
rAAV2/1-NF8-d1-GDNF-infected wells compared to rAAV2/1-
NF8-EGFP-infected wells (see Fig. 3A). We then tested whether
NFkB was activated in aging culture. Parallel cultures on coated
glass coverslips in 48 well cultures dishes were fixed at different
time points and processed for immunofluorescence using an
antibody recognizing the activated form of NFkB. The intensity of
the nuclear labeling was quantified and shown to increase with
time from day 10 to day 47 after seeding (Fig. 3B).
We further measured the concentrations of secreted GDNF in
the culture media. As shown in Figure 3C, the GDNF
concentration increased over time until 26 days post-infection
(corresponding to 31 days post-seeding), then decreased. The
GDNF decrease from 33 days post-infection (38 days post-seeding)
was presumably due to a reduced number of neurons in aging
Figure 4. Hippocampal sclerosis and upregulation of inflammatory markers in the hippocampus of kainic acid-treated rats. A.
Haematoxylin-eosin staining showing typical hippocampal sclerosis in kainic acid-treated rats (KA) (left) as compared to controls (right). Bar
represents 200 mm. B. Comparison of the intensity of the GFAP astrocytic marker staining in kainic acid- and saline-treated rats. Vibratome brain
sections (50 mm) were immunolabeled using mouse anti-GFAP followed by a secondary antibody coupled to Cy3 fluorophore. The intensity of the
staining of three random areas in the hipocampal layers on every section was quantified using the Image J program. Data are expressed as the mean
optical density 6 SEM (n= 8 for each group of animals). The difference between kainic acid and saline-treated groups was highly significant (student
test, P = 0,00018). Bar represents 500 mm. C. Comparison of the intensity of the CD11b staining of activated microglia in kainic acid- and saline-treated
rats. Vibratome brain sections (50 mm) were immunolabeled using mouse anti-CD11b followed by streptavidin-biotin-peroxidase staining. The
intensity of the staining of three random areas within the hippocampus on every section was quantified using the Image J program. Arrow shows
localized staining at the level of the needle tract. Data are expressed as the mean optical density 6 SEM (n = 4 for each group of animals). The
difference between kainic acid and saline-treated groups was significant (student test, P = 0,0068). Bar represents 200 mm. D. Comparison of the
intensity of the IbaI microglial staining in kainic acid- and saline-treated rats. Vibratome brain sections (50 mm) were immunolabeled using goat anti-
IbaI followed by anti-goat antibody coupled with cyanine 3. The intensity of the staining of three random areas within the hippocampus on every
section was quantified using the Image J program. Data are expressed as the mean optical density 6 SEM (n= 6 for each group of animals). The
difference between kainic acid and saline-treated groups was significant (student test, p = 0,00121). Bar represents 500 mm.
doi:10.1371/journal.pone.0053156.g004
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cultures which were previously shown to undergo apoptosis (data
not shown).
Altogether, these data suggest that GDNF expressed in response
to NFkB activation exert a protective effect on aging neurons.
3. Selective Induction of rAAV1-NF-mediated Gene
Expression in Hippocampal Neurons and Astrocytes in an
in vivo Model of Epilepsy
In order to show proof of principle of pathology-induced
expression from our new gene transfer vector in vivo, we tested its
activity in a KA-induced rat SE model for temporal lobe epilepsy
[16,36].
The rAAV2/1-NF8-d1 recombinant virus with an EGFP
reporter gene (86106 viral genomes in 2 ml) was injected in the
right hippocampus one month prior to SE induction. Eight
animals received KA and 8 control animals received an equivalent
number of saline injections.
Haematoxylin-eosin staining of coronal brain sections of KA-
treated rats showed typical hippocampal sclerosis whereas
hippocampus from saline-treated rats had a normal morphology
(Fig. 4A). Activated astrocytes and microglia were evidenced in
these regions as demonstrated by GFAP (Fig. 4B) CD11b (Fig. 4C)
and IbaI (Fig. 4D) stainings. Quantification of the staining by
optical density showed that GFAP, CD11b and IbaI expression
was significantly stronger in KA-treated versus saline treated
animals (for GFAP: p= 0.0003, n= 8 for each group; for CD11b:
p = 0.0135; n = 4 for each group; for IbaI: p = 0.0012; n = 6 for
each group).
Prominent gene expression was evidenced in the hippocampus
of KA-injected rats whereas only few dispersed GFP-positive cells
were detected in saline-injected animals (Fig. 5A). The regional
pattern of GFP expression in the SE animals consisted of a
preferential transduction of the CA1 and CA3 layers as well as an
occasional labeling of cells in the stratum oriens (see Fig. 5A).
Figure 5. Disease-inducible rAAV1-NF-mediated transgene
expression in the hippocampus of kainic acid-treated rats.
Recombinant AAV2/1-NF8-d1-EGFP (86106 vg) was stereotaxically
injected in the right hippocampus of male Wistar rats. Animals were
kept in two groups: one group was intraperitoneally-injected with
kainic acid (n = 8) one month post stereotaxy and the other group
received only saline (n = 8). The animals were sacrificed one week after
injection. Vibratome brain sections (50 mm) were immunolabeled using
an anti-GFP antibody, biotin-streptavidin amplification and Cy2
fluorophore. A. Representative examples of GFP-labeling of the CA
hippocampal layers dentate gyrus post-kainic acid injection. Note the
massive presence of GFP-positive cells in the CA1 and CA3 layers.
Stereological counts of GFP-positive cell numbers per animal demon-
strates a highly significant induction of the AAV-NF vector by kainic acid
(P = 0,000875; student test; n = 8 for the saline group; n = 6 for the kainic
acid group). KA, kainic acid; saline, 0.9% NaCl. The experiment was
repeated 3 times with similar results. Bars represent 500 mm and 100mm
in lower and higher (1,2,3 subpannels) magnification pictures,
respectively. B. Comparison of the staining intensity for activated NFkB
in kainic acid- and saline-treated rats. Vibratome brain sections (50 mm)
were immunolabeled using anti-activated NFkB antibody followed by
streptavidin-biotin-peroxidase staining. Note, in particular, the localized
increased staining in the CA hippocampal layers. The intensity of the
staining of three random areas in the hipocampal layers on every
section was quantified using the Image J program. Data are expressed
as the mean optical density 6 SEM (n= 8 for each group of animals).
The difference between KA and saline-treated groups was significant
(student test, P = 0.0010). Bars represent 500 mm. C. Correlation
between NFkB activation and GFP expression mediated by rAAV2/1-
NF8-d1-EGFP in hippocampal layers. A group of 16 rats was injected
with a rAAV1/2-NF8-d1-EGFP in the hippocampus. 8 rats were injected
with KA and 8 other animals were injected with the saline solution. Two
KA-treated rats were removed from the analysis since they either
contained no GFP-positive cells (presumably due to a failure to inject
the virus) or had a totally different profile of GFP-expression (no GFP-
positive cells in the hippocampal layers, presumably due to wrong
stereotaxic coordinates). The total number of GFP-immunoreactive cells
per animal (as evaluated by stereology was correlated with the mean
optical density of the NFkB stainings in the region containing the
transduced cells. There was a significant correlation between the two
parameters with a coefficient of 0.7001 (p = 0.0002; n = 6 for KA-treated
rats and n=8 for saline-treated rats). The experiment was repeated a
second time (n = 8 for KA-treated rats and n=7 for saline-treated rats)
with similar results.
doi:10.1371/journal.pone.0053156.g005
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GFP-positive cells were present in a region of 2.5 mm along the
antero-posterior axis (data not shown). Among the eight KA-
treated rats, one had no GFP-positive cell and in another rat the
biodistribution of gfp-positive cells was totally different (the
labeling was observed only in stratum orens and absent in the
hippocampal layers). It was considered that stereotaxic injections
of the virus were performed at slightly different coordinates in
these 2 animals and they were withdrawn for further analysis.
In order to correlate GFP expression with NFkB activation,
hippocampal sections were also labeled with antibodies directed
against activated NFkB. These results show a strong staining in
specific hippocampal subregions of epileptic rats corresponding to
the area in which GFP-positive cells were observed (see Fig. 5B).
The number of GFP-positive cells was also evaluated by
stereology and compared to the control group. The data showed
that the epileptic animals contained significantly more GFP-
positive cells than the control group (Fig. 5A). Furthermore a
significant correlation between the GFP positive cell numbers and
activated NFkB staining intensity per animal was observed with a
coefficient of 0.7001, (p = 0.0002) (Fig. 5C).
The majority of GFP-positive cells (60%) were neurons (as
revealed by double GFP-NeuN immunofluorescence and confocal
microscopy), with a smaller but nonetheless statistically significant
proportion (9.5%) of transduced cells comprising astrocytes (based
on co-labeling for the astrocytic marker GFAP) as well as 3.2% of
cells of the oligodendrocyte lineage (as revealed using the Olig2
Figure 6. Cellular specificity of rAAV2/1-NF8d1-EGFP-mediated gene transfer in the hippocampus of kainic acid-treated rats. Kainic
acid (5 mg/kg) was injected intraperitoneally (ip) one month after stereotaxic injection of rAAV2/1-NF8d1-EGFP into the hippocampus. Fifty mm
coronal sections were co-labeled with GFP (green fluorescence) and NeuN, GFAP IbaI or Olig2. Confocal pictures showing GFP and cell-specific
markers co-labeled cells (yellow). White arrows indicate co-labeled cells. Bars represent 50 mm. The mean percentage of GFP-positive cells co-labeling
with the GFAP, NeuN and Olig2 markers are shown. No GFP-positive cell stained positive for IbaI. Analysis was performed using confocal microscopy
and counting the number co-labeled cells on 5 sections per animal (n = 5 rats for GFP/NeuN and GFP/GFAP, n = 6 for GFP/IbaI and n= 7 for GFP/Olig2
co-labeling).
doi:10.1371/journal.pone.0053156.g006
Figure 7. Absence of transgene upregulation in rAAV2/1-NF8d1-EGFP-mediated gene transfer in the cerebellum of kainic acid-
treated rats. Kainic acid (5 mg/kg) was injected intraperitoneally (ip) one month after stereotaxic injection of rAAV2/1-NF8d1-EGFP into the
cerebellum. Fifty mm coronal sections were labeled with GFP or GFAP antibodies. Confocal pictures showing GFP (A) or GFAP (B). Bars represent
50 mm. GFAP staining was quantified by measuring the optical density of three area in all sections stained per animal (6 rats for each condition). The
difference between KA- and saline-treated rats is not significant (student test, p = 0,8612) (B).
doi:10.1371/journal.pone.0053156.g007
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marker [47] (Fig. 6). In contrast, double immunofluorescence for
GFP and the IbaI marker for microglia revealed no co-labeled cell
(Fig. 6).
The experiment was repeated a second time (n = 8 for the KA
group and n= 7 for the saline group) and similar results were
obtained (data not shown).
In order to further demonstrate that vector induction was
dependent on the KA-induced NFkB activation, the cerebellum
was selected as negative control vector injection site because lack
of NFkB activation following kainic acid administration to adult
rats was previously shown in this region [48]. As expected, i) GFP-
positive cells were restricted in a small area around the injection
site and their number was not increased by KA treatment (Fig. 7A);
ii) KA did not induce cerebellar inflammation as suggested by the
similar GFAP staining in treated and untreated rats (Fig. 7B).
Discussion
Abnormal activation of NFkB is a heavily implicated patho-
genic mechanism in a number of chronic neurodegenerative and
neuroinflammatory diseases [49]. In the CNS, neuroinflammation
propagates by communication between astrocytes, microglia and
neurons through the activity of pro-inflammatory cytokines such as
TNFa and IL1bwhich activate NFkB [50,51]. While neurons
require a basal level of activated NFkB for their survival [25],
uncontrolled neuronal activation results in excitotoxicity which
leads to further NFkB activation [52]. Our goal was to design a
gene transfer vector able to sense pathological increases of NFkB
activation.
In order to design a tight NFkB -responsive AAV vector, we first
selected a promoter sequence on the basis of previous studies with
tetracycline-inducible vectors. Strathdee and colleagues [43] have
previously compared the minimal thymidine kinase promoter
(mTK) and CMV promoter (mCMV) and reported that mTK
conferred a tighter control to a tetracycline-responsive promoter.
Unexpectedly, however, our test of 4 copies of the JC virus NFkB-
responsive element linked to the same two promoters showed that
the AAV-mTK-NF4 vector conveyed a high basal level of
expression and was poorly (less than 2-fold) inducible by TNFa
in HEK-293T cells. We have not explicitly tested the origin of this
high basal expression level, which could reflect activity of the
mTK promoter alone or together with a contribution from
incompletely blocked ITR enhancer activity.
To overcome the issues of high basal expression and poor
inducibility, we constructed and tested a new variant of a minimal
CMV promoter (mCMVD2). It is shown that mCMVD2
conferred to AAV-NF a lower basal transgene expression level
than the mTK promoter while exhibiting a higher (approx. 4-fold)
inducibility in response to TNFa.
To further reduce the basal level of transcription from
mCMVD2, we modified the distance between the viral cis-acting
elements (left ITR) and NFkB-RE and the TATA box of the
promoter. Increasing the distance to 31 (d1) and 71 bp (d3)
resulted in a further decrease (5- and 13- fold, respectively) of the
basal expression level. To increase the inducibility of the vector,
we have increased the number of NFkB-REs. The constructs
harbouring 8 REs (pSC-NF8-d1 and pSC-NF8-d3) had a higher
inducibility than those harbouring 4 REs (pSC-NF4-d1 and pSC-
NF4-d3) while retaining a similar background (for pSC-NF8-d3,
data not shown). This suggests that the basal expression of the
vector may depend more on the ITR than the NFkB-REs.
Increasing the number of NFkB-REs to 12 did not further increase
the inducibility but slightly reduced the basal level (compare pSC-
NF8-d1-EGFP versus pSC-NF12-d1-EGFP), possibly due to an
increase of the distance from the minimal promoter to the left
ITR.
Two models in which NFkB activation occurs were used to
prove the responsiveness of the optimized NFkB -inducible AAV
vector. These consisted of an in vitro model of neuronal aging and a
rat model of temporal lobe epilepsy.
NFkB involvement in the former is believed to result from
increases in inflammatory cytokines with age [20] and Alzheimer
Disease [21]. Additional data suggest that NFkB activation is not
an autocompensatory response, since NFkB activation fails to
protect neurons again apoptosis associated with long-term
culturing or dual TNFa and amyloid-beta toxicity [22].
GDNF has previously been shown to be neuroprotective in
animal models of brain aging [53] as well as to reduce apoptosis in
dopaminergic neurons [54]. In the current study, we show that
GDNF expression under the control of our NFkB-inducible vector
increased (by 40%) the number of aging cortical neurons in
culture. Our data suggest that it is feasible to harness age-related
NFkB activation to express neuroprotective factors in age-related
diseases.
A chronic inflammatory state in the brain has been associated
with epilepsy in both human and rodent studies [55–58]. In
addition, proinflammatory molecules exacerbate seizures in
experimental models, whereas anti-inflammatory drugs can have
anticonvulsant efficacy [59]. The observed reporter gene expres-
sion mediated by the NFkB-inducible AAV vector in the
hippocampus in response to systemic KA injection is in
accordance with these observations, and further suggests that
NFkB activation could be harnessed to drive expression of anti-
inflammatory genes. In addition, the cell-type specificity of GFP
expression might provide clues to the mechanisms of neuroin-
flammation in induction and progression of epileptic condition. As
expected, in the cerebellum, in which NFkB is not induced by
intraperitoneal injection of KA [48] AAV-NF-mediated GFP
expression remained at the basal level in epileptic rats.
Transgene expression was detected in neurons and cells of the
oligodendrocyte lineage showing that vector delivery and NFkB
activation occur in these 3 cell types in the KA model. NFkB
activation in neurons could reflect secondary neuroinflammation
in neurons by pro-inflammatory cytokines released by microglia
and/or neuron hyperactivity induced by the kainic acid model
itself [60].
In contrast, no GFP expression was evidenced in microglial
cells. This is surprising, since a NFkB response has been described
in microglia activated by the pro-inflammatory cytokine TNFa
[61] and KA treatment is known to induce pro-inflammatory
cytokines, including TNFa in the hippocampus [47].
The capsid serotype largely influences the cellular tropism of
AAV vectors in the CNS [62–65]. In rodents, the majority of AAV
serotypes or capsid variants, when injected in the rat parenchyma
mediate transgene expression mostly in neurons with notable
exceptions such as rAAV9 which mediates transgene expression in
both neurons and astrocytes (Foust et al., 2009) or rAAV4 which
transduce ependymal cells [66]. Interestingly, enhanced gene
delivery into astrocytes has been obtained by selecting AAV capsid
variants through molecular evolution [67].
In addition, we and others have previously shown that, the
promoter also influences the AAV-delivered transgene expression
profile [68,69]. Indeed, using a serotype 1 capsid, GFP was
exclusively expressed in neurons using the tetOn promoter
whereas 5% of GFP-positive cells were astrocytes with the CMV
promoter. In the present study, with the rAAV1-NF8-d1 vector,
we observed that 9.5% of GFP-positive cells in the hippocampal
CA1 and CA3 layers of epileptic rats were astrocytes whereas 60%
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were neurons. Whether these data reflect the proportion of
astrocytes and neurons in which NFkB has been activated by the
KA treatment or are biased by the tropism of the AAV serotype 1
capsid and mCMV promoter cannot be concluded from our data.
It remains to be determined if the use of other AAV serotypes
would modify the proportion of neurons, astrocytes and possibly
microglial cells expressing a transgene driven by the AAV-NF
vector. Furthermore, the optimal targeting of glial versus neuronal
cells may also vary by disease indication.
The onset of AAV-mediated transgene expression in the brain is
fairly slow [38]. However, serotype 1 AAV vectors are character-
ized by remarkably rapid kinetics in several regions of the brain
with maximal expression reached at 2 to 4 days post-injection [70];
[71]. In addition, self-complementary vectors that bypass the
limitation of second-strand viral DNA synthesis further reduce the
delay for transgene expression [70]; [29].
In conclusion, this study constitutes a proof-of-concept step
toward the use of NFkB-inducible AAV vectors for disease-
inducible transgene delivery to treat disorders of the nervous
system. Nonetheless, more data will be required to establish
whether transgene expression tightly follows the temporal course
of disease and whether pathology-appropriate cellular targeting of
the inflammatory response can be reliably achieved.
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